Autologous peripheral blood progenitor cell transplantation in patients with high-risk myelodysplastic syndromes.
Most patients with myelodysplastic syndromes (MDSs) who achieve a complete remission under aggressive chemotherapy develop a recurrence within 18 to 24 months. Autologous stem cell transplantation has therefore been suggested as a potential means of increasing treatment efficacy. As compared with bone marrow stem cell autografts, peripheral stem cell autografts have a higher harvesting yield and a shorter duration of aplasia after reinjection. Also, the results reported herein suggest that polyclonal stem cells harvested after chemotherapy-induced aplasia and growth factor therapy are capable of ensuring normal hematopoiesis and may provide prolonged remissions in some patients.
Verhoef
G E
GE
Department of Hematology, University Hospital Gasthuísberg, Leuven, Belgium.
Demuynck
H
H
Delforge
M
M
Vandenberghe
P
P
Maertens
J
J
Zachée
P
P
Boogaerts
M
M
D000328:Adult; D004359:Drug Therapy, Combination; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000628:therapy*; D012074:Remission Induction / Q000379:methods; D012307:Risk Factors